New drugs for the prevention and treatment of migraine: Topiramate and BIBN 4096 BS

Expert Opinion on Pharmacotherapy

Volumn 5, Issue 8, 2004, Pages 1837-1840

  Doggrell, Sheila A ^a  

^a Doggrell Biomedical Communications   (New Zealand)

Author keywords

BIBN 4096; Clinical trial; Migraine; Migraine attack; Migraine prevention; Topiramate

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; ANTIMIGRAINE AGENT; BIBN 4096 BS; CALCITONIN GENE RELATED PEPTIDE RECEPTOR; CANDESARTAN; KAINIC ACID RECEPTOR; PLACEBO; SEROTONIN 1 RECEPTOR; SEROTONIN 1B RECEPTOR; SUMATRIPTAN; TOPIRAMATE; UNCLASSIFIED DRUG; VALPROIC ACID;

ANOREXIA; ARTICLE; BODY WEIGHT DISORDER; CLINICAL TRIAL; DIARRHEA; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG BINDING SITE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; ENZYME INHIBITION; FATIGUE; HUMAN; HYPESTHESIA; INCIDENCE; MEMORY DISORDER; MIGRAINE; MORBIDITY; NAUSEA; NEUROTRANSMISSION; NONHUMAN; PARESTHESIA; TASTE DISORDER; VASODILATATION;

EID: 4344586318     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.5.8.1837     Document Type: Article

References (15)

1. OLSEN J, DIENER HC, HUSSTEDT IW et al.: Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N. Engl. J. Med. (2004) 350:1104-1110.
2. BRANDES JL, SAPER JR, DIAMOND M et al.: Topiramate for migraine prevention: a randomized controlled trial. JAMA (2004) 291: 965-973.
3. GOADSBY PJ, LIPTON RB, FERRARI MD: Migraine - current understanding and treatment. N. Engl. J. Med. (2002) 346:257-270.
4. STOREY JR, CALDER CS, HART DE, POTTER DL: Topiramate in migraine prevention: a double-blind, placebo-controlled study. Headache (2001) 41:968-975.
5. PASCUAL J, SANCHEZ DEL RIO M, MATEOS V et al.: Topiramate for patients with refractory migraine: an observational, multicenter study in Spain. Neurologia (2003) 18:364-367.
6. MARTINEZ HR, LONDONO O, CANTU-MARTINEZ, DEL CARMEN TARIN L, CASTILLO CD: Topiramate as an adjunctive treatment in migraine prophylaxis. Headache (2003) 43:1080-1084.
7. SILBERSTEIN SD, NETO W, SCHMITT J, JACOBS D: Topiramate in migraine prevention: results of a large controlled trial. Arch. Neurol. (2004) 61:490-495.
8. FREITAG FG, COLLINS SD, CARLSON BA et al.: A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis. Neurology (2002) 58:1652-1659.
9. TRONVIK E, STROVNER LJ, HELDE G, SAND T, BOVIM G: Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial. JAMA (2003) 289:65-69.
10. DOGGRELL SA. Migraine and beyond: cardiovascular therapeutic potential for CGRP modulators. Expert Opin. Investig. Drugs (2001) 10:1131-1138.
11. DOODS H, HALLERMAYER C, WU D et al.: Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist. Br. J. Pharmacol. (2000) 129:420-423.
12. MORENO MJ, ABOUNADER R, HEBERT E, DOODS H, HAMEL E: Efficacy of the non-peptide CGRP receptor antagonist BIBN4096BS in blocking CGRP-induced dilations in human and bovine cerebral arteries: potential implications in acute migraine treatment. Neuropharmacology (2002) 42:568-576.
13. THE SUBCUTANEOUS SUMATRIPTAN INTERNATIONAL STUDY GROUP: Treatment of migraine attacks with sumitriptan. N. Engl. J. Med. (1991) 325:316-321.
14. 1D agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet (2001) 358:1668-1675.
15. TEPPER SJ, MILLSON D: Safety profile of the triptans. Expert Opin. Drug Saf. (2003) 2:123-132.